Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-29
2011-03-29
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253090, C514S254020, C514S254050, C514S254080, C514S249000, C514S323000, C514S339000, C514S417000, C544S238000, C544S363000, C544S364000, C544S367000, C544S369000, C544S370000, C544S371000, C544S373000, C544S349000, C540S576000, C546S277100, C546S200000, C548S466000, C548S467000, C548S473000
Reexamination Certificate
active
07915260
ABSTRACT:
The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
REFERENCES:
patent: 6011050 (2000-01-01), Muller et al.
patent: 6884887 (2005-04-01), Riermeier et al.
patent: 6911464 (2005-06-01), Man et al.
patent: 7043052 (2006-05-01), Rhoads et al.
patent: 2004/0229871 (2004-11-01), Cesure et al.
patent: 2004/0259873 (2004-12-01), Man et al.
patent: 2004/0267051 (2004-12-01), Boerner et al.
patent: 2005/0143393 (2005-06-01), Dean et al.
patent: 2005/0203090 (2005-09-01), Man et al.
patent: 2005/0239867 (2005-10-01), Zeldis
patent: 2005/0282819 (2005-12-01), Graham
patent: WO 01/05741 (2001-01-01), None
patent: 02/47687 (2002-06-01), None
patent: WO 03/014061 (2003-02-01), None
patent: 03/104216 (2003-12-01), None
patent: WO 2004/080422 (2004-09-01), None
patent: WO 2004/080423 (2004-09-01), None
patent: WO 2004/0259873 (2004-09-01), None
patent: WO 2004/0259873 (2004-09-01), None
patent: WO 2005/034873 (2005-04-01), None
patent: WO 2005/034873 (2005-04-01), None
patent: WO 2005/072226 (2005-08-01), None
patent: WO 2005/072226 (2005-08-01), None
patent: 2007/008541 (2007-01-01), None
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Matsumoto et al, “Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents,” Neuroscience Letters, 2004, pp. 99-102, vol. 358, Elsevier Ireland Ltd.
Pearson et al, “Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes,” Proc. Natl Acad. Sci., 1980, pp. 5021-5024, vol. 77, No. 8, Physiological Sciences, USA.
Tal et al, “A Novel Putative Neuropeptide Receptor Expressed in Neural tissue, including Sensory Epiethelia,” Biochemical and Biophysical Research Communications, 1995, pp. 752-759, vol. 209, No. 2, Academic Press, Inc.
Marchese et al “Cloning and Chromosomal Mapping of Three Novel Genes, GPR9, GPR10, and GPR14, Encoding Receptors Related to Interleukin 8, Neuropeptide Y, and Somatostatin Receptors,” Genomics, 1995, pp. 335-344, vol. 29, Academic Press, Inc.
Douglas et al, “Human Urotensin-Ii, the Most Potent Mammalian Vasoconstrictor Identified to Date, as a Therapeutic Target for the Management of Cardiovascular Disease,” TCM, 2000, pp. 229-237, vol. 10, No. 6, Elsevier.
Zou et al, “Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats,” FEBS Letters, 2001, pp. 57-60, vol. 508, Elsevier Science B.V.
Bousette et al, “Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta,” Atherosclerosis, 2004, pp. 117-123, vol. 176, Elsevier Ireland Ltd.
Totsune et al, “Role of Urotensin II in patients on dialysis,” The Lancet, 2001, pp. 810-811, vol. 358, Research Letters.
Conlon et al, “Distribution and Molecular Forms of Urotensin II and Its Role in Cardiovascular Regulation in Vertebrates,” The Journal of Experimental Zoology, 1996, pp. 226-238, vol. 275, Wiley-Liss, Inc.
Totsune et al, “Increased plasma Urotensin II levels in patients with diabetes mellitus,” Clinical Science, The Biochemical Society and The Medical Research Society, 2003, pp. 1-5, vol. 104, Great Britain.
Gartlon et al, “Central effects of urotensin-II following ICV administration in rats,” Psychophaarmacology, 2001, pp. 426-433, vol. 155, Springer-Verlag.
Gartlon et al, “Urotensin-II, a neuropeptide ligand for GPR14, induces c-fosin the rat brain,” European Journal of Pharmacology, 2004, pp. 95-98, vol. 493, Elsevier.
Silvestre et al, “Inhibition of Insulin Release by Urotensin II—A Study on the Perfused Rat Pancreas,” Horm Metab Res., 2001, pp. 379-381, vol. 33, Georg Thieme Verlag Stuttgart, New York.
Ames et al, “Human urotensin-II is a potent vasoconstrictor and agonist for the Orphan Receptor GPR14,” Letters to Nature, 1999, pp. 282-286, vol. 401, Macmillan Magazine Ltd.
Lim et al, “Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients with Chronic Heart Failure,” Circulation, 2004, pp. 1212-1214, vol. 109, American Heart Association.
Watanabe et al, “Synergistic Effect of Urotensin II with Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells,” Circulation, 2001, pp. 16-18, vol. 104, American Heart Association.
International Search Report, PCT/US07/00644, Apr. 2007.
European Search Report, 07717845.7-2101/1993554, PCT/US2007000644, Jul. 2010.
Ghosh Shyamali
Kinney William A.
Lawson Edward C.
Luci Diane K.
Marchenko Nikolay
Bernhardt Emily
Stercho Yuriy P.
LandOfFree
Urotensin II receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urotensin II receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urotensin II receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711316